Literature DB >> 23890370

Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up.

N Gianotti1, L Galli, S Salpietro, M Cernuschi, S Bossolasco, M Maillard, V Spagnuolo, F Canducci, M Clementi, A Lazzarin, A Castagna.   

Abstract

Human immunodeficiency virus (HIV) -infected patients with HIV RNA loads of < 50 copies/mL were followed-up for a median (interquartile range) of 30.8 (11.7-32.9) months to study the effect of residual viraemia (RV) on virological rebound (VR). At baseline, 446 (60.3%) patients had undetectable HIV RNA (group A) and 293 (39.7%) had RV (1-49 HIV RNA copies/mL, group B) by kinetic PCR. VR occurred in 4 (0.9%) patients in group A and in 12 (4.1%) patients in group B (p 0.007). Time to VR was shorter among patients of group B (Log-rank test: p 0.003). However, the proportion of VR was extremely low also among patients with RV.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Antiretroviral therapy; human immunodeficiency virus type 1viral load; kinetic PCR; virological failure; virological rebound

Mesh:

Substances:

Year:  2013        PMID: 23890370     DOI: 10.1111/1469-0691.12266

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

1.  Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent for nucleic acid testing assays.

Authors:  Alessandra Amendola; Patrizia Marsella; Maria Bloisi; Federica Forbici; Claudio Angeletti; Maria R Capobianchi
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

2.  Full Viral Suppression, Low-Level Viremia, and Quantifiable Plasma HIV-RNA at the End of Pregnancy in HIV-Infected Women on Antiretroviral Treatment.

Authors:  Silvia Baroncelli; Maria F Pirillo; Enrica Tamburrini; Giovanni Guaraldi; Carmela Pinnetti; Anna Degli Antoni; Clementina M Galluzzo; Chiara Stentarelli; Roberta Amici; Marco Floridia
Journal:  AIDS Res Hum Retroviruses       Date:  2015-04-08       Impact factor: 2.205

3.  Reduced adherence to antiretroviral therapy is associated with residual low-level viremia.

Authors:  Franco Maggiolo; Elisa Di Filippo; Laura Comi; Annapaola Callegaro; Giorgio L Colombo; Sergio Di Matteo; Daniela Valsecchi; Marco Rizzi
Journal:  Pragmat Obs Res       Date:  2017-05-26

4.  INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels.

Authors:  Sidonie Lambert-Niclot; Anders Boyd; Djeneba Fofana; Nadia Valin; Marc Wirden; Jean-Luc Meynard; Romain Palich; Rachid Agher; Marc-Antoine Valantin; Vincent Calvez; Christine Katlama; Pierre-Marie Girard; Anne-Geneviève Marcelin; Laurence Morand-Joubert
Journal:  Open Forum Infect Dis       Date:  2019-04-10       Impact factor: 3.835

5.  Studying patterns and predictors of HIV viral suppression using A Big Data approach: a research protocol.

Authors:  Jiajia Zhang; Bankole Olatosi; Xueying Yang; Sharon Weissman; Zhenlong Li; Jianjun Hu; Xiaoming Li
Journal:  BMC Infect Dis       Date:  2022-02-04       Impact factor: 3.090

6.  Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.

Authors:  Nicola Gianotti; Andrea Poli; Laura Galli; Michela Franzin; Patrizia Tadini; Nadia Galizzi; Alessia Carbone; Marco Merli; Camilla Muccini; Chiara Oltolini; Andrea Andolina; Vincenzo Spagnuolo; Adriano Lazzarin; Antonella Castagna
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.